A Phase I Clinical Trial of Single-Dose Intrapleural IFN-{beta} Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: Hig
Source: PubMed
Results from a Phase 1 trial on the use of single-dose intrapleural interferon-beta gene transfer for patients with malignant pleural mesothelioma and metastatic pleural effusions show promise as a treatment regimen and should be further evaluated. Subjects in the study were evaluated for the following factors: (a) toxicity, (b) gene transfer, (c) humoral, cellular, and cytokine-mediated immune responses, and (d) tumor responses via PET scans and chest CT scans. Among the subjects, intrapleural interferon was generally well-tolerated. The results documented gene transfer in 7 of the 10 patients, while 4 of the 10 showed meaningful clinical responses, which were defined as disease stability and/or regression.
Results from a Phase 1 trial on the use of single-dose intrapleural interferon-beta gene transfer for patients with malignant pleural mesothelioma and metastatic pleural effusions show promise as a treatment regimen and should be further evaluated. Subjects in the study were evaluated for the following factors: (a) toxicity, (b) gene transfer, (c) humoral, cellular, and cytokine-mediated immune responses, and (d) tumor responses via PET scans and chest CT scans. Among the subjects, intrapleural interferon was generally well-tolerated. The results documented gene transfer in 7 of the 10 patients, while 4 of the 10 showed meaningful clinical responses, which were defined as disease stability and/or regression.
Labels: mesothelioma
posted by Belluck & Fox at
9:56 AM
© Belluck & Fox, L.L.P. All rights reserved.
